VICTORIA, Seychelles, June 30, 2026 /PRNewswire/ -- MEXC, a pioneer in 0-fee digital asset trading, continues to see explosive demand for its SpaceX-series products. Cumulative subscriptions across the two phases of the SPACEX(PRE) Launchpad surpassed $173 million, drawing over 74,000 participants, with the most popular pool oversubscribed 30 times. Since its IPO on June 12, the SPCXUSDT perpetual futures has accumulated over $7.1 billion in trading volume, with open interest (OI) peaking at $25 million — an increase of more than 26 times from its launch.
Launchpad Oversubscription Validates Market Demand
Both phases of the SPACEX(PRE) Launchpad were significantly oversubscribed. SPACEX(PRE) Phase 1 reached an oversubscription multiple of 15.5 times; after launching at a subscription price of 650 USDT, the price climbed as much as 27% to 830 USDT, fueling even greater interest in Phase 2. The most popular pool in Phase 2 was oversubscribed by more than 30 times, with a subscription price of just 130 USDT (a 30% discount). Following SpaceX's IPO on June 12, market attention quickly shifted to secondary-market futures trading.
Explosive Growth in Futures Trading
SPCXUSDT perpetual futures quickly became one of the platform's most popular instruments. In the two weeks following SpaceX's IPO, the product accumulated $7.13 billion in trading volume. Weekly trading activity continued to climb, with single-week volume up as much as 1,727%, and 10,532% compared with the first week.
Positioning metrics were equally strong. Open interest grew 2,687% from launch, indicating that traders are active not only in short-term flows but also in steadily building medium- and long-term positions. Weekly active futures traders increased as much as 806%, with growth broadly distributed across multiple regions. A long-short ratio holding near 1:1 points to a healthy, balanced participation structure, with no signs of one-sided crowding.
A Clear Wealth Effect: Gains of Up to 67% and Single-User Profits Reaching 60,000 USDT
Strong price performance further reinforced investor interest. SPACEX(PRE) posted a peak gain of 67%: the Phase 2 subscription price of 130 USDT climbed above 200 USDT after listing, generating more than 8 million USDT in aggregate profit potential for participants, with the highest individual gain reaching 60,000 USDT. By lowering the barrier to entry, MEXC Launchpad gives everyday users access to Pre-IPO opportunities in the world's leading technology companies at a comparatively modest minimum investment.
A Full-Cycle Product Matrix: From Pre-IPO to Real U.S. Equities
The enduring strength of the SPACEX-series validates deep user demand for exposure to top-tier global technology growth assets. To serve that demand, MEXC has built a three-tier product matrix spanning the entire SpaceX investment lifecycle:
- Pre-IPO Launchpad: low-barrier subscriptions that lock in pre-listing valuations early
- 0-Fee Perpetual Futures: flexible, two-way exposure to price movements
- RealStocks: real U.S. equities traded through licensed brokerage channels, with full dividend rights
From early-stage Pre-IPO valuations, to leveraged futures, to real U.S. stocks trading via licensed brokers, MEXC is building a one-stop gateway that bridges crypto liquidity and traditional financial assets, enabling users to move seamlessly from early discovery to long-term holding, all within a single platform.
Looking ahead, MEXC will continue to expand its cross-asset product lineup, helping users seize global market opportunities with greater flexibility within a familiar trading environment.
About MEXC
MEXC is the world's fastest-growing cryptocurrency exchange, trusted by more than 40 million users across 170+ markets. Built on a user-first philosophy, MEXC offers industry-leading 0-fee trading and access to over 3,000 digital assets. As the Gateway to Infinite Opportunities, MEXC provides a single platform where users can easily trade cryptocurrencies alongside tokenized assets, including stocks, ETFs, commodities, and precious metals.
MEXC Official Website｜ X ｜ Telegram ｜How to Sign Up on MEXC
Risk Disclaimer:
This content does not constitute investment advice. Given the highly volatile nature of the cryptocurrency market, investors are encouraged to carefully assess market fluctuations, project fundamentals, and potential financial risks before making any trading decisions.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
MEXC SpaceX Products See Surging Demand as Cumulative Futures Trading Volume Surpasses $7.1 Billion
HONG KONG, June 30, 2026 /PRNewswire/ -- U.S. News & World Report has again ranked The Chinese University of Hong Kong (CUHK)'s Faculty of Medicine (CU Medicine) No. 2 globally in Gastroenterology & Hepatology, maintaining a top-three position worldwide for four consecutive editions. The Faculty has also been crowned Asia's No. 1 in Gastroenterology & Hepatology and Endocrinology & Metabolism for five consecutive years, and in Clinical Medicine for the second consecutive year.
Overall, five CU Medicine disciplines rank among Asia's top three – Gastroenterology & Hepatology, Endocrinology & Metabolism, Clinical Medicine, Surgery, Radiology, Nuclear Medicine & Medical Imaging – while seven are ranked No. 1 in Hong Kong, namely Gastroenterology & Hepatology, Endocrinology & Metabolism, Clinical Medicine, Surgery, Radiology, Nuclear Medicine & Medical Imaging, Neuroscience & Behaviour, and Oncology, underscoring the Faculty's broad excellence in research, clinical care, and education.
Driving Breakthroughs in Gastroenterology & Hepatology
CU Medicine's sustained global prominence is driven by pioneering research and clinical innovation that continue to shape international clinical practice.
In gut microbiome research, CU Medicine leads the region through its Asia's first Microbiota Transplantation and Research Centre, pioneering in fecal microbiota transplantation (FMT), early-life microbiome research, and non-invasive diagnostics. Landmark discoveries include identifying novel microbiome biomarkers for autism spectrum disorders, as well as demonstrating that modulating gut microbiota may alleviate anxiety symptoms. In another world-first breakthrough, faculty researchers revealed that Streptococcus anginosus can cause gastric cancer, providing new insights for future clinical intervention.
CU Medicine has also been at the forefront of non-invasive and endoscopic innovation, transforming patient care by reducing surgical trauma and speeding recovery. The Faculty is the first in the world in pioneering endoluminal robotics for treatment of GI cancers. Today, CU Medicine also serves as the world's first testing ground for a novel AI-powered upper gastrointestinal endoscopy system, enhancing early cancer detection with greater precision using robotic technology.
The Faculty has also led major international initiatives, notably The Lancet Commission on liver cancer, marking a historic first in the journal's 200-year history as a major cancer report spearheaded by Hong Kong scholars. Five CU Medicine scholars, including one as the first author, formed the 51-strong commission with experts from the US, Europe, and Asia. This pivotal role reflects the powerful recognition of CU Medicine's contribution to and leadership in global liver cancer and disease research.
Bringing these bench-to-bedside capabilities directly to patient care, CU Medicine was the first in the world to define stool microRNA and bacterial biomarkers for the early, non-invasive diagnosis of colorectal cancer. In tandem with these diagnostic advancements, researchers recently revealed a novel "clear out–feed in" function of the macrophage subtype "TREM2+ LAM", which provides nutrients to cancer cells during the process of clearing apoptotic cells (efferocytosis), highlighting a new drug target for liver cancer immunotherapy.
Professor Philip Chiu, Dean of Medicine at CUHK, stated, "Sustaining a top-three position globally for four consecutive editions underscores the broad and enduring excellence of CU Medicine. True medical advancement requires the courage to pioneer what has never been done before, and our teams have proven that Hong Kong scholars can lead the world in clinical and scientific breakthroughs. Building on this momentum, we will continue to break boundaries, accelerate the translation of frontier research, and cultivate the next generation of globally minded, empathetic medical leaders."
About the Faculty of Medicine, The Chinese University of Hong Kong (CU Medicine)
Established in 1981, CU Medicine has earned international recognition for teaching, research, and clinical practice. The Faculty consistently ranks in the top 1% of over 4,000 medical schools worldwide. In the "Best Global Universities Subject Rankings 2026-27" by U.S. News and World Report, our "Gastroenterology and Hepatology," "Endocrinology and Metabolism," and "Clinical Medicine" programmes hold 1st place in Asia, while Gastroenterology and Hepatology has maintained its place among the global top three since 2022.
Our Faculty comprises 14 clinical departments and five schools, delivering a world-class environment for teaching and research with a strong emphasis on interdisciplinary, interprofessional, and international collaboration. To date, we have cultivated over 6,000 medical graduates who are making an impact across local and global healthcare systems. We are dedicated to driving innovation by translating groundbreaking research into real-world clinical applications. Our contributions have reshaped medicine — evidenced by the filing of 3,000 patents, strategic patent acquisitions, and the establishment of more than 20 start-ups. Our pioneering research has not only rewritten international clinical guidelines but also revolutionised the prevention, diagnosis, and treatment of numerous diseases.
Please visit http://www.med.cuhk.edu.hk for more information.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
CU Medicine Ranked World No. 2 in Gastroenterology & Hepatology
